Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14088892 | 0.95 | — | — | |
| SCHEMBL15830656 | 0.89 | — | — | |
| SCHEMBL9209118 | 0.85 | GRIN2D (0.32) | USP2ALDH1A1LMNACYP1A2TSHR | |
| SCHEMBL16985068 | 0.82 | USP2 (0.31) | USP2ALDH1A1LMNACYP1A2TSHR | |
| SCHEMBL158419 | 0.80 | USP2 (0.41) | USP2ALDH1A1LMNACYP1A2TSHR | |
| SCHEMBL15830654 | 0.80 | USP2 (0.34) | USP2ALDH1A1LMNACYP1A2TSHR | |
| SCHEMBL16547437 | 0.78 | — | — | |
| SCHEMBL19622331 | 0.78 | — | — | |
| SCHEMBL76375 | 0.78 | USP2 (0.44) | USP2ALDH1A1LMNACYP1A2TSHR | |
| SCHEMBL9968719 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023240024-A1 | SULFAMIDE DERIVATIVES AS CYCLIN-DEPENDENT KINASE 2 INHIBITORS | NIKANG THERAPEUTICS, INC. (US) | 2023-12-14 | — | — | WO | disclosed |
| US-20210219885-A1 | SENSOR ARRAY SYSTEMS AND METHODS FOR DETECTING MULTIPLE ANALYTES | ABBOTT DIABETES CARE INC. | 2021-07-22 | — | — | US | disclosed |
| US-9550793-B2 | Spirocyclic compounds, compositions and medicinal applications thereof | ADVINUS THERAPEUTICS LIMITED (IN) | 2017-01-24 | — | — | US | disclosed |
| EP-2707372-B1 | SPIRO-OXINDOLE MDM2 ANTAGONISTS | UNIV MICHIGAN REGENTS (US) | 2016-12-21 | — | — | EP | disclosed |
| US-9365499-B2 | 9-aminomethyl substituted tetracycline compounds | KBP BIOSCIENCES CO., LTD. (CN) | 2016-06-14 | — | — | US | disclosed |
| US-9302120-B2 | Spiro-oxindole MDM2 antagonists | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2016-04-05 | — | — | US | disclosed |
| US-20150218187-A1 | SPIROCYCLIC COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF | IMPETIS BIOSCIENCES LTD. (IN) | 2015-08-06 | — | — | US | disclosed |
| US-9079913-B2 | Spiro-oxindole MDM2 antagonists | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2015-07-14 | — | — | US | disclosed |
| US-9079913-B2 | Spiro-oxindole MDM2 antagonists | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2015-07-14 | — | — | US | disclosed |
| US-20140378680-A1 | SPIRO-OXINDOLE MDM2 ANTAGONISTS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2014-12-25 | — | — | US | disclosed |
| US-8518984-B2 | Spiro-oxindole MDM2 antagonists | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2013-08-27 | — | — | US | disclosed |
| US-8518984-B2 | Spiro-oxindole MDM2 antagonists | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2013-08-27 | — | — | US | disclosed |
| WO-2012155066-A2 | SPIRO-OXINDOLE MDM2 ANTAGONISTS | WANG SHAOMENG (US) | 2012-11-15 | — | — | WO | disclosed |
| WO-2012065022-A2 | SPIRO-OXINDOLE MDM2 ANTAGONISTS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2012-05-18 | — | — | WO | disclosed |
| US-20120122947-A1 | SPIRO-OXINDOLE MDM2 ANTAGONISTS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2012-05-17 | — | — | US | disclosed |
| US-20120122947-A1 | SPIRO-OXINDOLE MDM2 ANTAGONISTS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2012-05-17 | — | — | US | disclosed |
| WO-2011127058-A2 | BIOMARKERS FOR MDM2 INHIBITORS FOR USE IN TREATING DISEASE | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2011-10-13 | — | — | WO | disclosed |
| WO-2011060049-A2 | SPIRO-OXINDOLE MDM2 ANTAGONISTS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2011-05-19 | — | — | WO | disclosed |
| US-20110112052-A1 | SPIRO-OXINDOLE MDM2 ANTAGONISTS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2011-05-12 | — | — | US | disclosed |
| US-20110112052-A1 | SPIRO-OXINDOLE MDM2 ANTAGONISTS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2011-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150218187-A1 | SPIROCYCLIC COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF | DGAT1, DGAT2, CPT1A | USP2 4437/4885ALDH1A1 307/4885LMNA 1182/4885 |
| US-20140378680-A1 | SPIRO-OXINDOLE MDM2 ANTAGONISTS | TP53, MDM2, TP53BP1 | USP2 1933/4885ALDH1A1 1498/4885LMNA 2384/4885 |
| US-20110112052-A1 | SPIRO-OXINDOLE MDM2 ANTAGONISTS | TP53, MDM2, TP53BP1 | USP2 1933/4885ALDH1A1 1498/4885LMNA 2384/4885 |
| US-20120122947-A1 | SPIRO-OXINDOLE MDM2 ANTAGONISTS | TP53, MDM2, TP53BP1 | USP2 1933/4885ALDH1A1 1498/4885LMNA 2384/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.